Search

Displaying results 5621 - 5630 of 7018 in total
  1. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    Regarding the modifications of these UC-MSCs, CD362, also known as syndecan-2, is a surface marker identified on MSCs with enhanced clonogenicity and immunomodulatory properties. … ORBCEL-C™ is the trade name of a product composed of highly purified stromal cells derived from the human umbilical cord.

  2. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  3. Drug

    Hepatitis B immune globulin

    go.drugbank.com/drugs/DB05276
    ApprovedInvestigational

    Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. … It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed.

  4. Drug

    Chlorotoxin I-131

    go.drugbank.com/drugs/DB05462
    Investigational

    It is a synthetic version of a neurotoxin isolated from the venom of the Giant Yellow Israeli scorpion Leiurus quinquestriatus. … The synthetic version of this peptide has been manufactured and covalently linked to iodine 131 as a means of targeting radiation to tumor cells in the treatment of brain cancer.

  5. Drug

    ZYCOV-D

    go.drugbank.com/drugs/DB15892
    Experimental

    The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interest[L16503]. … As of August, 2020 the candidate is in Phase II clinical trials[A219758].

  6. Drug

    PV903

    go.drugbank.com/drugs/DB05163
    Experimental

    PV903 is a self administered vaginally delivered recombinant protein for the treatment of recurrent miscarriage, resulting from an intolerant immune response to the developing foetus.

  7. Drug

    Vanillic acid

    go.drugbank.com/drugs/DB02130
    Experimental

    A flavoring agent. It is the intermediate product in the two-step bioconversion of ferulic acid to vanillin. (J Biotechnol 1996;50(2-3):107-13).

  8. Drug

    Bifidobacterium Longum Infantis 35624

    go.drugbank.com/drugs/DB17871
    Experimental

    Bifidobacterium Longum Infantis 35624 is a probiotic being investigated for the treatment of gastrointestinal disorders, such as Crohn's disease and irritable bowel syndrome.[A259872, A259877]

  9. Drug

    TAS-106

    go.drugbank.com/drugs/DB06656
    Investigational

    TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].

  10. Drug

    Anatibant

    go.drugbank.com/drugs/DB05038
    Experimental

    Anatibant is a selective, very potent, small-molecule Bradykinin B2 receptor antagonist. It is developed for the for the treatment of traumatic brain injury (TBI).